Phase 3 trial, 102 adults with gastric cancer and limited peritoneal metastases: gastrectomy, cytoreductive surgery and HIPEC did not improve survival vs systemic therapy alone (median OS 15·7 vs 16·6 months; HR 1·10, p=0·70); serious adverse events 44% vs 6%.
RCTn = 102
Quik et al. Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis